Articles by Peter J. Pitts - Pharmaceutical Executive


Articles by Peter J. Pitts

Peter J. Pitts

Opinion: AARPeeved
November 1, 2006

Critics of the pharma industry have gotten good at selective reporting. So good, I've started tuning out. But, with a public official pulling similar punches, my ears can't help but perk up.

Opinion: Brussels Sprouts
May 1, 2006

I've just returned from Europe, where I spoke with various think tanks, thought leaders, and pharmaceutical companies on the issue they call "information-to-patients" (ItP). That's what we on the other side of the pond refer to as direct-to-consumer communications. In Europe, they choose to abstain from using the "A" word—advertising. But rhetoric counts. "Information to patients" seems quite paternalistic when compared with the new-worldly "direct-to-consumer" moniker.

Opinion: Uncle Sam, MD
June 1, 2005

Allowing the private sector to bear both the risk and the reward for successfully developing pharmaceutical, biologic, and medical technology products has been, and remains, the most successful, efficient way to meet our public health goals.

Back Page: Vioxx Populi
January 1, 2005

A congressional inquiry, a disgruntled whistle blower, the press smelling blood in the water, tort lawyers throwing blood in the water. What do they add up to? And does it really make patients safer?

Put More Science in Social Science
September 1, 2004

At FDA, science rules. Decisions are based on facts. But even facts require interpretation, and that task is done with verve, excellence, and dedication by the agency's world-class experts. But what about social science? How does the Division of Drug Marketing, Advertising, and Communications (DDMAC) engage social science to interpret vague concepts such as "fair balance" and "adequate provision"? The answer is that they know it when they see it-on a case-by-case basis. In common parlance, this is known as "judgment."


Click here